GlassScriptPhysician profile
Bruce L Mintz
NPI 1508834169
$6,774.60
in general payments reported to CMS, 2019-2025
45 companies · $722 in 2025
The $722 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $674 · 2021: $957 · 2022: $990 · 2023: $1,399 · 2024: $831 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307 · Long Term Medical Supply Or Device Loan: $628 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.24 |
| Long Term Medical Supply Or Device Loan | $627.75 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $967.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $748.23 | 2019-2024 | Xarelto |
| Cashflow Solutions, LLC | $652.54 | 2023-2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Lilly USA, LLC | $488.86 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $488.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $295.45 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $290.84 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.42 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $242.82 | 2019-2023 | Interlock |
| Astrazeneca Pharmaceuticals LP | $236.79 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $212.26 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $180.58 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $144.29 | 2019-2024 | Repatha, Otezla |
| Esperion Therapeutics, INC. | $124.73 | 2022 | |
| Shockwave Medical, INC | $122.96 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Mintz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.